Diabetic Neuropathy and Oxidative Stress: Therapeutic Perspectives
Abstract
1. Introduction
A conduction problem arising in peripheral nerves is called peripheral neuropathy. Depending on the cause, the damage may appear in the axons or the myelin sheaths. The involved neurons may be afferent (sensory), efferent (motor), or both. The size of affected axons is an important issue, since sometimes only the small C unmyelinated and the A-delta fibers are affected. If these are damaged, symptoms move forward to pain sensors in the skin and autonomic neurons. Damage to large sensory fibers, which are the A-alpha and A-beta fibers, causes deficits in the proprioception and vibration sensation that results in muscle-stretch reflexes [1].
Diabetic neuropathy (DN), a microvascular complication of diabetes, comprises disorders of peripheral nerve in people with diabetes when other causes are ruled out. Diabetic peripheral neuropathy (DPN) is associated with considerable mortality, morbidity, and diminished quality of life [2]. The prevalence of neuropathy in diabetic patients is about 30%, whereas up to 50% of patients will certainly develop neuropathy during their disease [3]. In fact, against estimated universal prevalence of diabetes of 472 million by 2030, DPN is likely to affect 236 million persons worldwide causing lots of costs [4]. DPN can be broadly divided into generalized polyneuropathies and focal/multifocal varieties [5, 6]. The generalized form can be further classified into typical and atypical in terms of difference in onset, course, associations, clinical manifestations, and pathophysiology. The typical DPN is a chronic, symmetrical length-dependent sensorimotor polyneuropathy (DSPN) and the most common presentation of the peripheral nervous system damage by diabetes [7]. Therefore, considering the widespread of DN, it is vital to investigate details of its pathophysiology and therapeutic strategies. DN develops on a background of hyperglycemia and associated metabolic imbalances mainly oxidative stress. Hyperglycemia-induced overproduction of free radicals has been recognized as the source of further complications. Studies in the recent years have identified major pathways that are linked to DN, such as stimulated polyol, advanced formation of glycation end products, and other cascades of stress responses [8]. Since oxidative stress leads to such a major influence in the development of DN, in this paper we have highlighted the evidence linking DN, oxidative stress, and its consequences.
Despite efforts to make an early diagnosis and to stop the progression of DN, currently very few drugs are available to cure this disease and the others only provide symptomatic relief. Meanwhile, current goal of treatment of DN is to increase the functionality and quality of life and to diminish pain. In the present review, therapies on the horizon based on oxidative stress have been criticized.
2. Methods
Databases of PubMed, Google Scholar, Web of Science, Embase, Scopus, and DARE were searched up to 30 November 2012, for all relevant studies with DN. The search terms were diabetic neuropathy, oxidative stress, mechanisms, and current and new treatments without limiting search elements. All of relevant human (Table 1) and animal (Table 2) studies were included.
3. Clinical Features of DN
The most common form of DN is DSPN that accounts for a large proportion of all peripheral nerve manifestations attributed to diabetes, although, some physicians use the terms DSPN and DN interchangeably. Poor control of blood glucose is an important risk factor for the development of DN starting in the toes and gradually progressing proximally. Once it is diagnosed in the lower limbs, it may develop to the upper limbs with sensory loss [4]. For example, a patient with painful sensory neuropathy due to diabetes might first complain of burning or itchy sensations or even pain in the feet that is called paresthesias. The symptoms distribute on a so-called “glove and stocking” manner, as it starts from the longest axons. The unmyelinated nerve endings in the epidermis are degenerated first [2]. Neuropathic pain is the most disabling symptom observed in around one-third of patients with DN and about 20% of all diabetic patients. Painful DN deleteriously influences quality of life, sleep, mood, and the ability to work [4].
4. Pathogenesis of DN: Interaction of Oxidative Stress with Other Physiological Pathways
Although development of DN is multifactorial and the exact pathogenic mechanism is yet to be understood, a number of theories can be described. The current belief is that hyperglycemia, activation of polyol, advanced glycation end products (AGEs), hexosamine, diacylglycerol/protein kinase C (PKC), oxidative stress, nitric oxide, and inflammation all play key roles in DN. Based on evidence, oxidative stress is involved in all the above pathways (see Figure 1). These mechanisms are described one by one in the next sections of this paper, and then a conclusion is made.
4.1. Hyperglycemia
Excess intracellular glucose is processed by increased flux via one or more glucose metabolism pathways, and thus prolonged hyperglycemia results in progress of chronic complications of diabetes including DN.
4.2. Role of Polyol
Hyperglycemia results in elevated intracellular glucose in nerves, leading to saturation of the normal glycolytic pathway. Extra glucose lightens up the polyol pathway and that produces sorbitol and subsequently fructose by aldose reductase and sorbitol dehydrogenase, respectively. Increased polyol flux causes intracellular hyperosmolarity by an accumulation of impermeable sorbitol and compensatory efflux of other osmolytes such as myoinositol, taurine, and adenosine. In turn, shortage of myoinositol results in exhaustion of phosphatidylinositol and withdraws creation of adenosine triphosphate (ATP). All these processes result in a reduced activity of Na+/K+-ATPase and PKC, impaired axonal transport and structural breakdown of nerves, and finally presents itself as abnormal action potential. Aldose reductase-mediated reduction of glucose to sorbitol is associated with consumption of NADPH, and since NADPH is required for regeneration of reduced glutathione (GSH), this directly contributes to oxidative stress. In addition, formation of fructose from sorbitol promotes glycation, depletes NADPH, and increases AGEs which all result in major redox imbalance (see Figure 2) [9, 10].
4.3. Role of Advanced Glycation End Products (AGEs)
Hyperglycemia accelerates generation of AGEs via attachment of reactive carbohydrate groups to proteins, nucleic acids, or lipids. These groups tend to damage the biological task of proteins, which as a result affects cellular function. Extracellular AGEs also bind to the receptor of AGE (RAGE) and initiate inflammatory flows, activate NADPH oxidases, and generate oxidative stress. Long-term inflammatory responses upregulate RAGE and stimulate nuclear factor kappa B (NFκB). Collectively, the biochemical damage induced by AGEs results in diminished neurotrophic support, impaired nerve blood flow, disrupted neuronal integrity, and impaired repair mechanisms (Figure 2) [3, 10].
4.4. Role of Hexosamine
The hexosamine, an additional factor, is implicated in the pathology of diabetes-induced oxidative stress and its complications. Fructose-6 phosphate, a metabolic intermediate of glycolysis, is shifted from the glycolytic pathway to the hexosamine way where fructose-6 phosphate is converted to uridine diphosphate-N-acetylglucosamine (UDPGlcNAc). Then, the UDPGlcNAc attaches to the serine and threonine residues of transcription factors. Hyperglycemic conditions create additional flux through hexosamine pathway that ultimately result in an increased activation of Sp1, a transcription factor implicated in diabetic complications. Activation of Sp1 leads to overexpression of transforming growth factor-β1 (TGF-β1) and plasminogen activator inhibitor-1 (PAI-1). The PAI-1 is upregulated by both hexosamine and PKC pathways. Collectively, activation of hexosamine pathway is implicated in multiple metabolic derangements in diabetes (see Figure 2) [9].
4.5. Activation of Diacylglycerol Protein Kinase C
Hyperglycemia stimulates formation of diacylglycerol, which then activates PKC. The PKC is an important element in function of nerves and pathogenesis of DN. Activation of PKC initiates an intracellular signaling cascade such as overexpression of PAI-1, NF-κB, and TGF-β. It also increases the production of extracellular matrix and cytokines. Furthermore, it enhances contractility, permeability, and vascular endothelial cell proliferation such as motivation of cytosolic phospholipase A2 and inhibition of Na+/K+ ATPase (Figure 2) [9, 11]. PKC has a unique structural feature that according to redox status of cell facilitates its regulation. An antioxidant can react with catalytic domain to inhibit its activity, while the prooxidants react with regulatory domain to stimulate its activity. On activation, PKC triggers stress genes that phosphorylate transcription factors and thus alter the balance of gene expression resulting in oxidative stress [8].
4.6. Role of Oxidative Stress, Apoptosis, and Poly ADP-Ribose Polymerase
The generation of free radicals is a major factor in development of DN through increased glycolytic process. Oxidative stress and reactive oxygen species (ROS) link the physiological mediators and metabolic initiators implicated in progressive nerve fiber damage, dysfunction, and loss in DN. Simultaneous with generation of free radicals during the glycolytic process, oxidative stress harms mitochondrial DNA, proteins, and membranes [9, 12]. In fact, mitochondrial damage takes place due to surplus formation of ROS or reactive nitrogen species (RNS). Hyperglycemia induces mitochondrial changes such as release of cytochrome C, activation of caspase 3, altered biogenesis and fission, which all lead to a programmed cell death. Reduced mitochondrial action potentials (MMP) with modest ATP are resulted from thrilling entrance of glucose. This process results in surplus transport of oxidant electrons into the mitochondria. Neurotrophic support such as neurotrophin-3 (NT-3) and nerve growth factor (NGF) are also reduced by mitochondrial injury. It should be noted that axons are disposed to hyperglycemic hurt owing to their large content of mitochondria [12]. Oxidative stress in conjunction with hyperglycemia activates poly ADP-ribose polymerase (PARP) which further cleaves nicotinamide adenine dinucleotide (NAD+) to nicotinamide and ADP-ribose residues. This process continues by a link to nuclear proteins and results in changes of gene transcription and expression, NAD+ depletion, oxidative stress, and diversion of glycolytic intermediates to other pathogenic pathways such as PKC and AGEs (Figure 2) [9]. Collectively, the polyol, AGEs, PKC, hexosamine, and PARP, all contribute to neuronal damage together. The AGEs and polyol pathways openly modify the redox capacity of the cell either through weakening of necessary components of glutathione recycling or by direct construction of ROS. The hexosamine, PKC, and PARP pathways are representatives of damage mediated through expression of inflammatory proteins [9].
4.7. Nitric Oxide Deficiency/Impaired Endothelial Function
Vascular factors include impaired nerve perfusion, hypoxia, and nerve energetic defects that are all implicated in the pathogenesis of DN. Nerve blood flow is reduced in DN perhaps mediated via nitric oxide (NO). Overproduction of superoxide anion by the mitochondrial electron transport chain in DN leads to binding of this anion to NO to form the strong oxidant peroxynitrite which is right lethal to endothelial cells. Endothelial cells also produce NO that acts as a vasodilator and antagonizes thrombosis. The NO also defends against inflammation by adjusting (Na+/K+)-ATPase or inhibiting the production of potent vasoconstrictor peptide endothelin (ET)-1 [13, 14]. In addition, hyperhomocysteinemia is associated with impairment of endothelial function, providing a mechanism for its possible involvement in DN. There is a synergistic effect between AGEs and homocysteine in initiation of endothelial damage (Figure 2) [13].
4.8. Inflammation
The nerve tissues in diabetes undergo a proinflammatory process that presents symptoms and develops neuropathy. In addition, inflammatory agents such as C-reactive protein and tumor necrosis factor-α (TNF-α) are present in the blood of both type 1 diabetes (T1D) and type 2 diabetes (T2D) patients. The levels of C-reactive protein and TNF-α correlate with the incidence of neuropathy. Production of the initiating inflammatory mediators such as TNF-α, TGF-β, and NF-κB results from several glucose-induced pathways. Cyclooxygenase-2 (COX-2) is an important enzyme that is upregulated by NF-κB in diabetic peripheral nerves and consecutively generates prostaglandin E2 and ROS that trigger NF-κB. Inducible nitric oxide synthase (iNOS) is an additional inflammatory enzyme which is regulated by NF-κB. Similar to COX-2, iNOS either induces NF-κB or is induced by it. This gives the impression that chronic NF-κB activation is in the center of all the inflammatory elements operating in DN. Subsequent to ischemia reperfusion, an extensive and modest infiltration of macrophages and granulocytes takes place in diabetic peripheral nerves. The cytokines which are induced by NF-κB in Schwann cells, endothelial cells, and neurons lead to absorption of macrophages in the diabetic nerves. Macrophages promote DN via a variety of mechanisms, including making of cytokines, ROS, and proteases, which all result in cellular oxidative damage and myelin breakdown. Excessive macrophage recruitment impairs regeneration of nerves in DN [9, 12].
4.9. Growth Factors
Neurotrophic factors play roles in the development, maintenance, and survival of neuronal tissue. In DN, the Schwann cells are damaged and neurons disintegrate, and the growth factors such as NGF, NT-3 and insulin-like growth factors (IGFs) are affected [9, 11].
5. Differences in the Pathophysiology of T1D and T2D in DN
As noted, hyperglycemia is a fundamental factor in DN. Dyslipidemia and changes in insulin signaling come after hyperglycemia in T2D. Levels of both insulin and C-peptide are reduced in patients with T1D while the neuronal insulin sensitivity is reduced in T2D. Therefore, the circumstances of disease in T1D and T2D are different, and this affects the efficacy of some medications [3].
5.1. Dyslipidemia
Dyslipidemia with high incidence in T2D is linked to DN. Free fatty acids have systemic effects such as release of inflammatory cytokine from adipocytes and macrophages. Plasma lipoproteins, especially low-density lipoproteins (LDLs), can be modified by glycation or oxidation where then binds to extracellular receptors comprising the oxidized LDL receptor 1(LOX1), toll-like receptor 4(TLR4), and RAGEs that activate NADPH oxidase. All these result in oxidative stress. Additionally, cholesterol can be simultaneously oxidized to oxysterols to cause neuronal apoptosis (Figure 2) [3].
5.2. Impaired Insulin Signaling
Insulin has neurotrophic effects and promotes neuronal growth and the survival while it is not involved in uptake of glucose into the neurons. Reduction of this neurotrophic signaling due to insulin resistance (T2D) or insulin deficiency (T1D) contributes to the pathogenesis of DN. In neurons, insulin resistance occurs by inhibition of the PI3K/Akt signalling pathway. Disruption of this pathway leads to mitochondrial dysfunction, oxidative stress, and dysfunction or death of the nerve. Tight glucose control is not as efficacious in patients with T2D, whereas it can reduce neuropathy in patients with T1D. This divergence is most likely related to differences in the underlying mechanisms in terms of hyperglycemia, dyslipidemia, and insulin resistance in T1D and T2D [3].
6. Treatment of DN
6.1. Control of Hyperglycemia
As discussed above, hyperglycemia and/or insulin deficit and their concomitant actions are principally involved in the pathogenesis of DN. Thus, glycemic control gives the impression to be the most effective treatment to delay onset of DN and slowing its progress [14]. By contrast with the results obtained from patients with T1D, glucose control produces less definitive effect in patients with T2D. Therefore, despite the similarities between T1D and T2D, there are dissimilarities in the mechanisms and complications. It seems that glucose control is the only disease-modifying therapy for DN, as uncontrolled diabetes results in a pronounced oxidative stress that can be reversed if patients attain glycemic control. According to assumption that oxidative stress may mediate vascular, microvascular, and specific tissue complications in diabetes, antioxidant therapy remains a vital therapy [3]. Pain management is the other buttress of treatment for DN that can largely improve the quality of patients' life. As shown in Table 1, over the past two decades, enormous efforts have been made by doing randomized placebo-controlled trials to find effective treatments for DN. Based on these studies, several classes of drugs are considered to be effective for the treatment of DN, and also given the pathogenesis of DN, other drugs have been suggested as disease modifying all based on oxidative stress (Figure 3).
6.2. Current Pharmacotherapy of DN Independent of Oxidative Stress
6.2.1. Tricyclic Antidepressants (TCAs)
The TCAs are recommended as the first-line therapy to relief pain of DPN for many years, even though they are not specifically endorsed for it. TCAs besides affecting catecholamines, they inhibit sodium and calcium channels, adenosine and N-methyl-D-aspartate (NMDA) receptors on the way to suppress neuronal hyperexcitability. TCAs have many side effects, principally anticholinergic effects [98, 99]. A meta-analysis based on number needed to treat (NNT) for TCAs resulted in the scores of 2 to 3 with a number needed to harm (NNH) of 14.7 [100].
6.2.2. Selective Serotonin Reuptake Inhibitors (SSRIs) andSerotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Because of the relative high rate of adverse effects and several contraindications of TCAs, the SSRIs can be considered for those who do not tolerate TCAs. The SSRIs inhibit presynaptic reuptake of serotonin but not norepinephrine, and unlike TCAs, they lack postsynaptic receptor blocking effects and quinidine-like membrane stabilization. There is limited evidence showing a beneficial role for SSRIs, as they have not been licensed for the treatment of DN pain [14, 99, 101]. Antidepressants with dual selective inhibition of serotonin and norepinephrine (SNRIs) such as duloxetine and venlafaxine are better. SNRIs block the noradrenaline and 5-HT transporters and inhibit monoamine reuptake from the synaptic cleft into the presynaptic terminal which finally result in inhibition of excitatory impulse and pain perception [98, 101–103].
6.2.3. Anticonvulsants
Gabapentin and pregabalin should be used as first-line treatment for DPN pain if there is inadequate response or contraindications to TCAs. Pregabalin and gabapentin bind to the alpha2-delta subunit of the calcium-sensitive channels on the presynaptic neuron and modulate neurotransmitter release [99, 100]. Based on the new guidelines, pregabalin is recommended for the treatment of painful DN [102, 103]. Sodium valproate is probably effective in lessening pain and should be considered for the treatment of painful DN, but its adverse effects are high. For instance, it can worsen glycemic control and weight gain. Lamotrigine, oxcarbazepine and lacosamide should probably not be considered for the treatment of painful DN. Topiramate also lacks adequate support to be used in DN [103].
6.2.4. Opioids
Opioids by interacting with receptors located on neuronal cell membranes prevent neurotransmitter release at the presynaptic nerve terminal and reduce pain [14]. Controlled-release oxycodone, tramadol, and morphine can be exampled [99]. A meta-analysis indicated an NNT of 2.6 for oxycodone, 3.9 for tramadol, and 2.5 for morphine [100] in the treatment of painful DN [103].
6.2.5. Topical Medications
Current topical treatments for DPN pain include capsaicin cream and lidocaine 5% patches. This combination stimulates C fibers to release, and subsequently deplete substance P. Capsaicin application causes degeneration of epidermal nerve fibers as a mechanism of its analgesic effect, and thus caution for its use in insensitive diabetic foot is needed [14]. In a 2009 pooled data analysis, the calculated NNT for capsaicin was 5.7 [53]. Lidocaine blocks voltage-gated channels in damaged nerves [99]. There have been small effective trials with lidocaine. A randomized controlled trial (RCT) in 2003 revealed an NNT of 4.4 for it [67]. Topical clonidine is probably not effective and should not be considered [103].
6.2.6. Antipsychotics
Few atypical antipsychotics have been introduced for painful DN. The newer, less dopamine selective antipsychotics was supported by some animal studies consistent with clinical trials [104]. These compounds may induce negative metabolic effects such as weight gain and insulin resistance [105].
6.2.7. Anesthetics/Antiarrhythmic
These agents are all potent voltage-gated sodium channel antagonists and perhaps are less used in DN [105]. Mexiletine, lidocaine, and tocainide have all shown benefits for painful DN in smaller RCTs. Although tocainide has positive effects, but caution is needed for its cardiotoxicity [105]. Mexiletine has not been found effective [103]. The easiest method to incorporate the utility of the anesthetic/antiarrhythmics in patients with painful DN is the use of 5% lidocaine patches [105].
6.2.8. Vasodilators
Isosorbide dinitrate nasal spray and glyceryl trinitrate transdermal patches have shown positive effects in painful DN [105].
6.2.9. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
In patients with acute painful peripheral neuropathy, simple analgesics such as NSAIDs may provide pain control by modulating the nociceptive and inflammatory pain pathways [14].
6.2.10. NMDA Antagonists
Dextromethorphan, a low affinity NMDA receptor blocker, has been effective in relieving pain and improving quality of life in patients with DN [103].
6.2.11. Botulinum Toxin
This toxin not only works on the acetylcholine channels but also involves other mechanisms. Existing studies lack large number of subjects, and more is required to overcome doubt and debate about efficacy of this toxin [105].
6.3. Treatments Dependent on Oxidative Stress
The strongest sign for the role of oxidative stress in DN is the studies that report positive effects of antioxidants in both animal models and patients. Although, it is impossible to review all the antioxidants that can be effective to prevent or delay the onset of DN, some can be listed such as acetyl-L-carnitine, taurine, β-carotene, free amino acids, vitamin E, curcumin, ascorbic acid, and lipoic acid [8].
6.3.1. Taurine
Taurine is an antioxidant with effects on neuronal calcium signaling. Taurine improves electrophysiological parameters and nerve blood flow and exhibits analgesic properties in patients with DN [14].
6.3.2. Acetyl-L-Carnitine
Acetyl-L-carnitine (ALC), the acetylated ester of the amino acid L-carnitine, as an antioxidant has shown significant reduction in pain of patients with DN [14].
6.3.3. Alpha Lipoic Acid
D-L-α-lipoic acid (ALA) is a potent antioxidant, which has been extensively evaluated in subjects with DN and has shown good effects [14]. But based on new guidelines, there is insufficient evidence to recommend it in treatment of DN [103].
6.4. Nonpharmacologic Agents
Percutaneous electrical nerve stimulation is probably effective in reducing pain and improving sleep in patients who have painful DN. Exercise and acupuncture lack evidence of efficacy in the treatment of painful DN. Low-intensity laser therapy, Reiki therapy, and electromagnetic field treatment (such as magnetized shoe insoles) are probably not effective and should not be considered [103].
6.5. Therapies on the Horizon Based on Oxidative Stress
Since constant tight glucose control is difficult and still a challenge in most cases, additional therapies that target the hyperglycemia-induced complications are now under attention of researchers. To this end, coping against some known pathways that are activated as a consequence of increased oxidative stress and glucose flux is deemed effective to control DN. These pathways and inhibition of them are reviewed below.
6.5.1. Protein Kinase C Inhibitors
It is thought that activation of PKC through hyperglycemia-induced oxidative stress contributes to the generation of free radicals that result in diabetic microvascular complications [14]. Some of the PKC inhibitors such as ruboxistaurin have been shown to exhibit antioxidant effects. Ruboxistaurin has been particularly successful in reducing the progress of DN, and it is pending to get official approval [106].
6.5.2. Aldose Reductase Inhibitors (ARIs)
As stated earlier, hyperglycemia-mediated activation of the polyol pathway can produce oxidative stress that may underlie DN. Aldose reductase is a key enzyme in pathogenesis of DN. ARIs drop the flux of glucose through the polyol or sorbitol pathways resulting in a reduction of intracellular accumulation of sorbitol and fructose [14]. The effects of fidarestat (a novel ARIs) on nerve conduction and the subjective symptoms of DN provided evidence that this treatment can control DN with concomitant reduction in oxidative stress markers [107]. Similarly long-term treatment with epalrestat, an ARI, can effectively delay the progress of DN and improve the symptoms, particularly in subjects with limited microangiopathy and good glycemic control [108]. Treatment with ranirestat (ARIs) also appears to have an effect on motor nerve function in mild to moderate diabetic sensorimotor polyneuropathy (DSP), but the results of this study did not show a statistically significant difference in sensory nerve function relative to placebo [109].
6.5.3. Advanced Glycation End Product Inhibitors (AGEIs)
Accumulation of AGEs and activation of AGE receptors lead to oxidative stress and microvascular damage in DN. Benfotiamine, a derivative of thiamine (vitamin B1), reduces tissue AGEs formation and oxidative stress in subjects with DN with varying doses and duration of treatment [14, 110]. Also aspirin, because of its antioxidant capacity, and aminoguanidine, a free radical scavenger, can inhibit this pathway and reduce oxidative stress in DN [9].
6.5.4. Hexosamine Pathway Inhibitors
As described above, diabetes-induced oxidative stress stimulates hexosamine pathway that implicates in the pathology of DN. Benfotiamine decreases flux through hexosamine pathway resulting in lower oxidative stress. This agent can reduce the pain associated with DN [9].
6.5.5. Inhibition of PARP
As discussed above, PARP activation involves in the pathogenesis of DN, and its inhibition lightens numerous experimental pathologic conditions connected with oxidative stress in DN. Nicotinamide has been shown to act as a PARP inhibitor and an antioxidant in animals that improves complications of early DN [9].
6.5.6. Angiotensin Converting Enzyme Inhibitors
Angiotensin II is a potent vasoconstrictor with proinflammatory properties, which especially in the absence of NO causes thrombosis. It also stimulates intercellular adhesion molecules and vascular adhesion molecules (VCAMs). The role of angiotensin converting enzyme inhibitors in DN is probably through inhibition of angiotensin II. In this regard, trandolapril has shown a small but significant improvement in some complication of DN [14].
7. New Therapeutic Approaches for DN
Despite relative lack of success of interventional agents to reverse or slow established DN, there is still hope to find some good agents. We have summarized a few of new approaches in Table 2 [79–97]. Hopefully, some reviews in the recent years have proven positive effects of natural antioxidants and herbal products such as Satureja species and Urtica dioica in diabetes and its complications [111–116].
8. Conclusion
In the present review, we tried to elaborate the pathogenesis of disease with a focus on oxidative stress and introduced therapies dependent or independent of oxidative stress. Diabetes can injure peripheral nerves in various distributions, and DSPN is the most common presentation in diabetes, which lead to substantial pain, morbidity, and impaired quality of life. Social and health-care costs linked with DN are high. DN develops on a background of hyperglycemia and associated metabolic imbalance. Numerous biochemical mechanisms of neurovascular and nerve damage have been identified in DN, but excessive production of ROS or oxidative stress is thought to be a common etiologic factor.
Treatment of DN always begins with optimizing glycemic control and then control of pain. Regarding role of oxidative stress and consequential factors in pathogenesis of DN, observing positive results with inhibitors of key pathways at the preclinical level is not surprising, but final decision will be made on the basis of clinical trials. If oxidative stress is assumed only as an ancillary player in DN, then antioxidants should be supplemented with conventional treatments. Development of new drugs to treat DN still remains a challenge that needs intensive long-term comparative trials.
Mechanisms of diabetic neuropathy. The AGE and polyol pathways directly alter the redox capacity of the cell either through depletion of necessary components of glutathione recycling or by direct formation of ROS. The hexosamine, PKC, and PARP pathways indicate damage through expression of inflammation proteins. Dyslipidaemia with high incidence in T2D also linked to DN, and several underlying mechanisms have been identified. AGEs: advanced glycation end products; RAGEs: receptor for advanced glycation end products; NF-κB: nuclear factor kappa B; AD: aldose reductase; SDH: sorbitol dehydrogenase; GSH: glutathione; GSSG: oxidized glutathione; F-6-P: fructose-6 phosphate; UDPGlcNAc: uridine diphosphate-N-acetylglucosamine; PAI-1: plasminogen activator inhibitor-1; TGF-β1: transforming growth factor-β1; DAG: diaceylglycerol; PKC: protein kinase C; ROS: reactive oxygen species; RNS: reactive nitrogen species; PARP: poly ADP-ribose polymerase; Mt: mitochondria; MMPs: mitochondrial membrane potentials; Cyc: cytochrome c; NO: nitric oxide; LDL: low-density lipoprotein; LOX1: oxidised LDL receptor 1; TLR4: toll-like receptor 4; FFA: free fatty acids; TG: triglycerides; HDL: high-density lipoprotein; CyK: cytokine.
Algorithm for treatment of DN pain. TCAs: tricyclic antidepressants; SSRIs: selective serotonin reuptake inhibitors; SNRIs: serotonin norepinephrine reuptake inhibitors; NSAIDs: nonsteroidal anti-inflammatory drugs; ALC: acetyl-l-carnitine; ALA: α-lipoic acid; PKCIs: protein kinase C inhibitors; ARIs: aldose reductase inhibitors; AGEIs: advanced glycation end product inhibitors; GF: growth factor; PARPIs: poly ADP-ribose polymerase inhibitors; ACEIs: angiotensin converting enzyme inhibitors; HXIs: hexosamine pathway inhibitors.
| NNT | Study outcome | Treatment duration | Study design | Daily dose (mg) | Trial size | Trial | Drug used | Drug class |
|---|---|---|---|---|---|---|---|---|
| — | Amitriptyline > placebo | 2 × 6 wk | Crossover | Up to 150 mg | 29 | Max [15] | Amitriptyline | Antidepressants: TCAs: |
| 2.1 | Amitriptyline > placebo | 2 × 6 wk | Crossover | ≤150 mg | 29 | Max et al. [16] | Amitriptyline | |
| 2.2 | Amitriptyline = desipramine > placebo | 2 × 6 wk | Crossover | Amitriptyline: 105 mg; desipramine: 111 mg | 38 | Max et al. [17] | Amitriptyline and desipramine | |
| — | Amitriptyline > maprotiline > placebo | 4 wk | Crossover | 75 mg | 37 | Vrethem et al. [18] | Amitriptyline and maprotiline | |
| — | Amitriptyline > placebo | 2 × 6 wk | Crossover | 25–75 mg | 24 | Morello et al. [19] | Amitriptyline | |
| — | Clomipramine > desipramine > placebo | 6 wk | Crossover | Desipramine: 200 mg and clomipramine: 75 mg (in extensive metabolisers). 50 mg of both drugs (in poor metabolisers) | 19 | Sindrup et al. [20] | Desipramine and clomipramine | |
| Desipramine > placebo | 6 wk | Crossover | 201 mg | 20 | Max et al. [21] | Desipramine | ||
| — | Imipramine > placebo | 5 + 5 wk | Crossover | 100 mg | 12 | Kvinesdal et al. [22] | Imipramine | |
| — | Combination > placebo | 8 wk | Crossover | Nortriptyline: 10 mg; fluphenazine: 0.5 mg | 18 | Gomez-Perez et al. [23] | Nortriptyline and fluphenazine | |
| — | Citalopram > placebo | 2 × 3 wk | Crossover | 40 mg | 15 | Sindrup et al. [24] | Citalopram | SSRI: |
| — | Venlafaxine + gabapentin > placebo in patients who do not respond to gabapentin | 2 × 8 wk | Parallel | — | 11 and 42 | Simpson [25] | Venlafaxine and gabapentin | SNRIs |
| 5.2 for venlafaxine and 2.7 for imipramine. | Venlafaxine > imipramine > placebo | 4 wk | Crossover | Venlafaxine: 225 mg; imipramine: 150 mg | 29 | Sindrup et al. [26] | Venlafaxine versus imipramine | |
| 4.5 | Venlafaxine > placebo | 6 wk | Parallel | 150–225 mg | 244 | Rowbotham et al. [27] | Venlafaxine | |
| — | Venlafaxine > placebo | 8 wk | Parallel | 75–150 mg | 60 | Kadiroglu et al. [28] | Venlafaxine | |
| 11 (60 mg group); 5 (120 mg group) | Duloxetine > placebo | 12 wk | Parallel | 60, 120 mg | 348 | Raskin et al. [29] | Duloxetine | |
| 4.3 (60 mg group); 3.8 (120 mg group) | Duloxetine > placebo | 12 wk | Parallel | 20, 60, 120 mg | 457 | Goldstein et al. [30] | Duloxetine | |
| 6.3 (60 mg group); 3.8 (120 mg group) | Duloxetine > placebo | 12 wk | Parallel | 60, 120 mg | 334 | Wernicke et al. [31] | Duloxetine | |
| 5.2 and 4.9 (duloxetine 60 mg once daily and 60 mg BID, resp.) | Duloxetine > placebo | 3 × 12 wk | Parallel | 60 mg | 1024 | Kajdasz et al. [32] | Duloxetine | |
| 3.6 (300 mg group); 3.3 (600 mg group) | Pregabalin (300, 600 mg) > placebo | 5 wk | Parallel | 75, 300, 600 mg | 338 | Lesser et al. [33] | Pregabalin | |
| 3.9 | Pregabalin > placebo | 8 wk | Parallel | 300 mg | 146 | Rosenstock et al. [34] | Pregabalin | |
| 4.2 (600 mg group) | Pregabalin (600 mg) > placebo | 6 wk | Parallel | 150, 600 mg | 246 | Richter et al. [35] | Pregabalin | |
| 3.6 | Flexible and fixed > placebo | 12 wk | Parallel | Flexible: 150, 300, 450, 600 mg; fixed: 300, 600 mg | 338 | Freynhagen et al. [36] | Pregabalin | |
| 6.3 (600 mg group) | Pregabalin (600 mg) > placebo | 12 wk | Parallel | 150, 300, or 600 mg | 395 | Tölle et al. [37] | Pregabalin | |
| — | Pregabalin > placebo | 13 wk | Parallel | 600 mg | 167 | Arezzo et al. [38] | Pregabalin | |
| 4.04 (600 mg group); 5.99 (300 mg group); 19.06 (150 mg group) | 150, 300, 600 mg TID > placebo; 600 mg BID > placebo | 5 to 13 wk | Parallel | 150, 300, 600 mg administered TID or BID | — | Freeman et al. [39] | Pregabalin | |
| 4 | Gabapentin > placebo | 8 wk | Parallel | Titrated from 900 to 3600 mg | 165 | Backonja et al. [40] | Gabapentin | |
| — | Gabapentin = placebo | 2 × 6 wk | Crossover | 900 mg | 40 | Gorson et al. [41] | Gabapentin | |
| — | Sodium valproate > placebo | 4 wk | Parallel | 600–1200 mg | 52 | Kochar et al. [42] | Sodium valproate | |
| — | Sodium valproate > placebo | 16 wk | Parallel | 500 mg | 39 | Kochar et al. [43] | Sodium valproate | Anticonvulsants: |
| — | Sodium valproate = placebo | 4 wk | Crossover | 1500 mg | 31 | Otto et al. [44] | Sodium valproate | |
| 4 | Lamotrigine > placebo | 6 wk | Parallel | Titrated from 25 to 400 mg | 59 | Eisenberg et al. [45] | Lamotrigine | |
| — | Lamotrigine = placebo | 19 wk | Parallel | 200, 300, 400 mg | 360 | Vinik et al. [46] | Lamotrigine | |
| — | Lamotrigine = amitriptyline | 6 wk | Crossover, | Lamotrigine: 25, 50, 100 mg twice daily; amitriptyline: 10, 25, 50 mg at night time | 53 | Jose et al. [47] | Lamotrigine and amitriptyline | |
| — | Carbamazepine > placebo | 2 wk | Crossover | 200–600 mg | 30 | Rull et al. [48] | Carbamazepine | |
| — | Oxcarbazepine > placebo | 16 wk | Parallel | 300 mg titrated to a maximum dose of 1800 mg | 146 | Dogra et al. 2005 [49] | Oxcarbazepine | |
| 7.9 (1200 groups); 8.3 (1800 groups) | Oxcarbazepine > placebo (1200, 1800 mg groups) | 16 wk | Parallel | 600, 1200, 1800 mg | 347 | Beydoun et al. [50] | Oxcarbazepine | |
| — | Oxcarbazepine = placebo | 16 wk | Parallel | 1200 mg | 141 | Grosskopf et al. [51] | Oxcarbazepine | |
| — | Lacosamide > placebo | — | Parallel | 400 mg | 94 | Rauck et al. [52] | Lacosamide | |
| — | Lacosamide (400 mg group) > placebo | 18 wk | Parallel | 200, 400, 600 mg | — | Wymer et al. [53] | Lacosamide | |
| 3.1 | Tramadol > placebo | 6 wk | Parallel | 210 mg | 131 | Harati et al. [54] | Tramadol | |
| 4.3 | Tramadol > placebo | 2 × 4 wk | Crossover | 200–400 mg | 45 | Sindrup et al. [55] | Tramadol | |
| — | Tramadol/acetaminophen > placebo | 8 wk | Parallel | Tramadol: 37.5 mg; acetaminophen: 325 mg | 311 | Freeman et al. [56] | Tramadol/ acetaminophen | |
| — | Oxycodone > placebo | 6 wk | Parallel | 10–100 mg | 159 | Gimbel et al. [57] | Oxycodone | Opioids: |
| 2.6 | Oxycodone > placebo | 4 wk | Crossover | 10–80 mg | 45 | Watson et al. [58] | Oxycodone | |
| — | Oxycodone + gabapentin > placebo + gabapentin | 12 wk | Parallel | Oxycodone: 10–80 mg + gabapentin: 100–3600 mg | 338 | Hanna et al. [59] | Oxycodone | |
| — | Morphine + gabapentin > morphine > gabapentin > placebo | 4 × 4 wk | Crossover | 120, 60 mg morphine + 2400 mg gabapentin, 3600 mg gabapentin | 57 | Gilron et al. [60] | Morphine | |
| — | Capsaicin > vehicle | 8 wk | Parallel | 0.075% capsaicin | 252 | Anonymous et al. [61] | Capsaicin | |
| — | Capsaicin > vehicle | 8 wk | Parallel | 0.075% capsaicin | — | Scheffler et al. [62] | Capsaicin | |
| — | Capsaicin > vehicle | 8 wk | Parallel | 0.075% capsaicin four times a day | 22 | Tandan et al. [63] | Capsaicin | |
| — | Capsaicin > vehicle | 8 wk | Parallel | 0.075% capsaicin four times a day | Anonymous et al. [64] | Capsaicin | Topical medications: | |
| — | Isosorbide > placebo | 2 × 4 wk | Crossover | 30 mg | 22 | Yuen et al. [65] | Isosorbide dinitrate spray | |
| — | Glyceryl > placebo | 2 × 4 wk | Crossover | — | 48 | Agrawal et al. [66] | Glyceryl trinitrate spray | |
| 4.4 | Lidocaine > placebo | 4 wk | Crossover | 5% lidocaine patch | 40 | Meier et al. [67] | Lidocaine patch | |
| — | Lidocaine significantly improved pain and quality of life | 3 wk study with a 5 wk extension | Open label, flexible dosing | 5% lidocaine patch | 56 | Barbano et al. [68] | Lidocaine patch | |
| — | Mexiletine > placebo | 10 wk | Crossover | 10 mg | 16 | Dejgard et al. [69] | Mexiletine | Anesthetics/ antiarrhythmics: |
| Mexiletine > placebo | 3 wk | Parallel | 675 mg | 216 | Oskarsson et al. [70] | Mexiletine | ||
| — | Mexiletine = placebo | 3 wk | Parallel | 600 mg | 29 | Wright et al. [71] | Mexiletine | |
| 4 | Dextromethorphan > placebo | 2 × 6 wk | Crossover | Mean 381 mg | 14 | Nelson et al. [72] | Dextromethorphan | NMDA antagonists: |
| 3.2 | Dextromethorphan > placebo | 2 × 9 wk | Crossover | 400 mg | 19 | Sang et al. [73] | Dextromethorphan | |
| 3.03 at 12 weeks | Botulinum toxin > placebo | 24 wk | Parallel | Intradermal of subtype A (20–190 units) into the painful area | 29 | Ranoux et al. [74] | Botulinum toxin | Other drugs: |
| — | Botulinum toxin > placebo | 12 × 12 wk | Crossover | 50 units of subtype A in 1.2 mL 0.9% saline given intradermally into each foot, each injection 4 U subtype A | 18 | Yuan et al. [75] | Botulinum toxin | |
| — | Improved pain and nerve fiber regeneration | 2 × 52 wk | Parallel | 500 and 1,000 mg, three times per day | — | Sima et al. [76] | Acetyl-L-carnitine | |
| — | α-lipoic acid = placebo | 28 wk | Parallel | 600 mg | 509 | Ziegler et al. [77] | α-lipoic acid | |
| — | α-lipoic acid ≥ placebo with clinically meaningful degree | 3 wk | Parallel | 600 mg | 1258 | Ziegler et al. [78] | α-lipoic acid | |
| Endpoint | Study populations | Compound | Study |
|---|---|---|---|
| Improvement of peripheral nerve function | Diabetic rats | Salvianolic acid A | Yu et al. [79] |
| Improvement of DN | Animal model of T2D | High-fat diet with menhaden oil | Coppey et al. [80] |
| Improvement of DN | Patients with T2D and neuropathy | Tai Chi exercise | Ahn and Song [81] |
| Improvement of DN | T2DM patients | Beraprost sodium | Shin et al. [82] |
| Improvement of DN | STZ-diabetic rats | Anandamide | Schreiber et al. [83] |
| Improvement of peripheral nerve function | Mouse model of DPN | Thymosin β4 | Wang et al. [84] |
| Improvement of chronic pain, including PDN | Rat model of STZ-induced PDN | Gastrodin | Sun et al. [85] |
| Prevention of progression of DN | Patients enrolled in the aldose reductase inhibitor-diabetes complications | Epalrestat | Hotta et al. [86] |
| Improvement of DN | STZ-diabetic rats | Gliclazide with curcumin | Attia et al. [87] |
| Improvement of DN | STZ-diabetic rats | Bone marrow-derived mononuclear cells | Naruse et al. [88] |
| Neuroprotection effect | In vitro model of high glucose-treated DRG neurons in culture | Galanin | Xu et al. [89] |
| Improvement of DN | — | Baicalein | Yorek [90] |
| Improvement of neuropathic pain | Animal models of neuropathic pain | Brazilian armed spider venom toxin Tx3-3 | Dalmolin et al., [91] |
| Neuroprotection effect Improvement of DN | STZ-diabetic rats | Magnesium-25 carrying porphyrin-fullerene nanoparticles | Hosseini et al. [92, 93] |
| Maintaining health in diabetes | STZ-diabetic rats | Phosphodiesterase inhibitors | Milani et al. [94] |
| Improve transplant outcome and graft function in diabetes | Isolated rat pancreatic islets | IMOD | Larijani et al. [95] |
| Improve islet transplantation in diabetes | Isolated rat pancreatic islets | Cerium and yttrium oxide nanoparticles | Hosseini and Abdollahi [96, 97] |
Acknowledgment
This paper is the outcome of an in-house financially nonsupported study prepared for the special issue of Oxidative Medicine and Cellular Longevity. Author thanks assistance of INSF.
References
- 1. Peripheral Neuropathyhttp://courses.washington.edu/conj/neuron/peripheralNeuropathy.htm
- 2. Treatments for DNJournal of the Peripheral Nervous System201222227[Google Scholar]
- 3. Diabetic neuropathy: clinical manifestations and current treatmentsThe Lancet Neurology2012116521534[PubMed][Google Scholar]
- 4. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathyDiabetes—Metabolism Research and Reviews20121814[Google Scholar]
- 5. Classification, differential diagnosis, and staging of diabetic peripheral neuropathyDiabetes1997462S54S57[PubMed][Google Scholar]
- 6. Diabetic neuropathies: a statement by the American Diabetes AssociationDiabetes Care2005284956962[PubMed][Google Scholar]
- 7. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatmentsDiabetes Care2010331022852293[PubMed][Google Scholar]
- 8. Oxidative stress and diabetic neuropathy: current status of antioxidantsInstitute of Integrative Omics and Applied Biotechnology2011267178[Google Scholar]
- 9. Diabetic neuropathy: mechanisms to managementPharmacology & Therapeutics20081201134[PubMed][Google Scholar]
- 10. Diabetic neuropathy: therapies on the horizonJournal of Pharmacy and Pharmacology200961911371145[PubMed][Google Scholar]
- 11. A brief review on the pathogenesis of human diabetic neuropathy: observations and postulationsInternational Journal of Diabetes and Metabolism2005133135140[PubMed][Google Scholar]
- 12. Mechanism of diabetic neuropathy: where are we now and where to go?Journal of Diabetes Investigation2011211832[PubMed][Google Scholar]
- 13. Peripheral neuropathy: pathogenic mechanisms and alternative therapiesAlternative Medicine Review2006114294329[PubMed][Google Scholar]
- 14. Update on the management of diabetic polyneuropathiesDiabetes, Metabolic Syndrome and Obesity20114289305[Google Scholar]
- 15. Endogenous monoamine analgesic systems: amitriptyline in painful diabetic neuropathyAnesthesia Progress1987344123127[PubMed][Google Scholar]
- 16. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed moodNeurology1987374589596[PubMed][Google Scholar]
- 17. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathyThe New England Journal of Medicine19923261912501256[PubMed][Google Scholar]
- 18. A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabeticsClinical Journal of Pain1997134313323[PubMed][Google Scholar]
- 19. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy painArchives of Internal Medicine19991591619311937[PubMed][Google Scholar]
- 20. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over studyBritish Journal of Clinical Pharmacology1990305683691[PubMed][Google Scholar]
- 21. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trialPain199145139[PubMed][Google Scholar]
- 22. Imipramine treatment of painful diabetic neuropathyJournal of the American Medical Association19842511317271730[PubMed][Google Scholar]
- 23. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over studyPain1985234395400[PubMed][Google Scholar]
- 24. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathyClinical Pharmacology and Therapeutics1992525547552[PubMed][Google Scholar]
- 25. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathyJournal of Clinical Neuromuscular Disease2001325362[PubMed][Google Scholar]
- 26. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trialNeurology200360812841289[PubMed][Google Scholar]
- 27. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled studyPain20041103697706[PubMed][Google Scholar]
- 28. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitusJournal of Diabetes and its Complications2008224241245[PubMed][Google Scholar]
- 29. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic painPain Medicine200565346356[PubMed][Google Scholar]
- 30. Duloxetine vs. placebo in patients with painful diabetic neuropathyPain20051161-2109118[PubMed][Google Scholar]
- 31. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic painNeurology200667814111420[PubMed][Google Scholar]
- 32. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studiesClinical Therapeutics2007291125362546[PubMed][Google Scholar]
- 33. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trialNeurology2004631121042110[PubMed][Google Scholar]
- 34. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trialPain20041103628638[PubMed][Google Scholar]
- 35. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trialJournal of Pain200564253260[PubMed][Google Scholar]
- 36. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimensPain20051153254263[PubMed][Google Scholar]
- 37. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind studyEuropean Journal of Pain2008122203213[PubMed][Google Scholar]
- 38. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trialBMC Neurology20088, article 33[PubMed][Google Scholar]
- 39. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of dosesDiabetes Care200831714481454[PubMed][Google Scholar]
- 40. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. A randomized controlled trialJournal of the American Medical Association19982802118311836[PubMed][Google Scholar]
- 41. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trialJournal of Neurology Neurosurgery and Psychiatry1999662251252[PubMed][Google Scholar]
- 42. Sodium valproate in the management of painful neuropathy in type 2 diabetes—a randomized placebo controlled studyActa Neurologica Scandinavica20021065248252[PubMed][Google Scholar]
- 43. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled studyQJM20049713338[PubMed][Google Scholar]
- 44. Valproic acid has no effect on pain in polyneuropathy: a randomized, controlled trialNeurology2004622285288[PubMed][Google Scholar]
- 45. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled studyNeurology2001573505509[PubMed][Google Scholar]
- 46. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studiesPain20071281-2169179[PubMed][Google Scholar]
- 47. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathyDiabetic Medicine2007244377383[PubMed][Google Scholar]
- 48. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trialDiabetologia196954215218[PubMed][Google Scholar]
- 49. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled studyEuropean Journal of Pain200595543554[PubMed][Google Scholar]
- 50. Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging studyActa Neurologica Scandinavica20061136395404[PubMed][Google Scholar]
- 51. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathyActa Neurologica Scandinavica20061143177180[PubMed][Google Scholar]
- 52. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled studyClinical Journal of Pain2007232150158[PubMed][Google Scholar]
- 53. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimensClinical Journal of Pain2009255376385[PubMed][Google Scholar]
- 54. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathyNeurology199850618421846[PubMed][Google Scholar]
- 55. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trialPain19998318590[PubMed][Google Scholar]
- 56. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathyCurrent Medical Research and Opinion2007231147161[PubMed][Google Scholar]
- 57. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trialNeurology2003606927934[PubMed][Google Scholar]
- 58. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathyPain20031051-27178[PubMed][Google Scholar]
- 59. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patientsEuropean Journal of Pain2008126804813[PubMed][Google Scholar]
- 60. Morphine, gabapentin, or their combination for neuropathic painThe New England Journal of Medicine20053521313241334[PubMed][Google Scholar]
- 61. Treatment of painful diabetic neuropathy with topical capsaicin: a multicenter, double-blind, vehicle-controlled study. The Capsaicin Study GroupArchives of Internal Medicine19911511122252229[PubMed][Google Scholar]
- 62. Treatment of painful diabetic neuropathy with capsaicin 0.075%Journal of the American Podiatric Medical Association1991816288293[PubMed][Google Scholar]
- 63. Topical capsaicin in painful diabetic neuropathyDiabetes Care1992151814[PubMed][Google Scholar]
- 64. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Capsaicin Study GroupDiabetes Care1992152159165[PubMed][Google Scholar]
- 65. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over studyDiabetes Care2002251016991703[PubMed][Google Scholar]
- 66. Glyceryl trinitrate spray in the management of painful diabetic neuropathy: a randomized double blind placebo controlled cross-over studyDiabetes Research and Clinical Practice2007772161167[PubMed][Google Scholar]
- 67. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled studyPain20031061-2151158[PubMed][Google Scholar]
- 68. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathyArchives of Neurology2004616914918[PubMed][Google Scholar]
- 69. Mexiletine for treatment of chronic painful diabetic neuropathyLancet198818575-8576911[PubMed][Google Scholar]
- 70. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathyDiabetes Care1997201015941597[PubMed][Google Scholar]
- 71. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathyAnnals of Pharmacotherapy19973112934[PubMed][Google Scholar]
- 72. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgiaNeurology199748512121218[PubMed][Google Scholar]
- 73. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trialsAnesthesiology200296510531061[PubMed][Google Scholar]
- 74. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic painAnnals of Neurology2008643274283[PubMed][Google Scholar]
- 75. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trialNeurology2009721714731478[PubMed][Google Scholar]
- 76. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trialsDiabetes Care20052818994[PubMed][Google Scholar]
- 77. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic NeuropathyDiabetes Care199922812961301[PubMed][Google Scholar]
- 78. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a meta-analysisDiabetic Medicine2004212114121[PubMed][Google Scholar]
- 79. Salvianolic acid A protects the peripheral nerve function in diabetic rats through regulation of the AMPK-PGC1α-Sirt3 axisMolecules20121791121611228[PubMed][Google Scholar]
- 80. Partial replacement with menhaden oil improves peripheral neuropathy in high-fat-fed low-dose streptozotocin type 2 diabetic ratJournal of Nutrition and Metabolism201220128 pages[PubMed][Google Scholar]
- 81. Effects of Tai Chi Exercise on glucose control, neuropathy scores, balance, and quality of life in patients with type 2 diabetes and neuropathyJournal of Alternative and Complementary Medicine2012181211721178[PubMed][Google Scholar]
- 82. The effect of oral prostaglandin analogue on painful diabetic neuropathy: a double-blind, randomized, controlled trialDiabetes, Obesity and Metabolism2012152185188[Google Scholar]
- 83. Peripheral antinociceptive effect of anandamide and drugs that affect the endocannabinoid system on the formalin test in normal and streptozotocin-diabetic ratsNeuropharmacology201263812861297[PubMed][Google Scholar]
- 84. Thymosin β4 promotes the recovery of peripheral neuropathy in type II diabetic miceNeurobiology of Disease2012483546555[PubMed][Google Scholar]
- 85. Gastrodin inhibits allodynia and hyperalgesia in painful DN rats by decreasing excitability of nociceptive primary sensory neuronsPLoS ONE201276[PubMed][Google Scholar]
- 86. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathyDiabetic Medicine2012291215291533[PubMed][Google Scholar]
- 87. Protective effects of combined therapy of gliclazide with curcumin in experimental DN in ratsBehavioural Pharmacology2012232153161[PubMed][Google Scholar]
- 88. Transplantation of bone marrow-derived mononuclear cells improves mechanical hyperalgesia, cold allodynia and nerve function in DNPLoS ONE2011611[PubMed][Google Scholar]
- 89. The effects of galanin on dorsal root ganglion neurons with high glucose treatment in vitroBrain Research Bulletin20128718593[PubMed][Google Scholar]
- 90. Treatment of DN with baicalein: intervention at multiple sitesExperimental Neurology20112322105109[PubMed][Google Scholar]
- 91. Antinociceptive effect of Brazilian armed spider venom toxin Tx3-3 in animal models of neuropathic painPain20111521022242232[PubMed][Google Scholar]
- 92. Benefit of magnesium-25 carrying porphyrin-fullerene nanoparticles in experimental diabetic neuropathyInternational Journal of Nanomedicine201051517523[PubMed][Google Scholar]
- 93. Protective effect of magnesium-25 carrying porphyrin-fullerene nanoparticles on degeneration of dorsal root ganglion neurons and motor function in experimental DNBasic & Clinical Pharmacology & Toxicology20111095381386[PubMed][Google Scholar]
- 94. Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in ratsComparative Biochemistry and Physiology Part C20051402251255[PubMed][Google Scholar]
- 95. Positive response of isolated rat pancreatic islets to IMOD; hopes for better transplant outcome and graft functionAsian Journal of Animal and Veterinary Advances201161010191025[Google Scholar]
- 96. It is time to formulate an antioxidant mixture for management of diabetes and its complications: notice for phannaceutical industriesInternational Journal of Pharmacology2012816061[Google Scholar]
- 97. Through a mechanism-based approach, nanoparticles of cerium and yttrium may improve the outcome of pancreatic islet isolationJournal of Medical Hypotheses and Ideas2012646[Google Scholar]
- 98. New perspectives on the management of diabetic peripheral neuropathic painDiabetes and Vascular Disease Research200632108119[PubMed][Google Scholar]
- 99. Treating diabetic peripheral neuropathic painAmerican Family Physician2010822151158[PubMed][Google Scholar]
- 100. Algorithm for neuropathic pain treatment: an evidence based proposalPain20051183289305[PubMed][Google Scholar]
- 101. Painful diabetic neuropathy: advantage of novel drugs over old drugs?Diabetes care200932S414419[PubMed][Google Scholar]
- 102. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trialsBMC Neurology20088, article 29[PubMed][Google Scholar]
- 103. AAN, AANEM, and AAPMR publish guideline for treatment of painful diabetic neuropathAmerican Family Physician2012865469470[Google Scholar]
- 104. Antipsychotics for acute and chronic pain in adultsCochrane Database of Systematic Reviews20084[PubMed][Google Scholar]
- 105. Diabetic neuropathic pain: real world treatment optionsClinical Medicine Insights: Therapeutics20124169183[Google Scholar]
- 106. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trialClinical Therapeutics200527811641180[PubMed][Google Scholar]
- 107. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group studyDiabetes Care2001241017761782[PubMed][Google Scholar]
- 108. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trialDiabetes Care200629715381544[PubMed][Google Scholar]
- 109. Ranirestat for the management of diabetic sensorimotor polyneuropathyDiabetes Care200932712561260[PubMed][Google Scholar]
- 110. Benfotiamine in the treatment of diabetic polyneuropathy—a three-week randomized, controlled pilot study (BEDIP study)International Journal of Clinical Pharmacology and Therapeutics20054327177[PubMed][Google Scholar]
- 111. A review on the role of antioxidants in the management of diabetes and its complicationsBiomedicine and Pharmacotherapy2005597365373[PubMed][Google Scholar]
- 112. Islet transplantation and antioxidant management: a comprehensive reviewWorld Journal of Gastroenterology2009151011531161[PubMed][Google Scholar]
- 113. A systematic review of iranian medicinal plants useful in diabetes mellitusArchives of Medical Science200843285292[PubMed][Google Scholar]
- 114. A systematic review of in vitro studies conducted on effect of herbal products on secretion of insulin from Langerhans isletsJournal of Pharmacy & Pharmaceutical Sciences2012153447466[PubMed][Google Scholar]
- 115. An update on pharmacology of Satureja species; from antioxidant, antimicrobial, antidiabetes and anti-hyperlipidemic to reproductive stimulationInternational Journal of Pharmacology201064454461[PubMed][Google Scholar]
- 116. A systematic review of efficacy and safety of urtica dioica in the treatment of diabetesInternational Journal of Pharmacology201172161170[PubMed][Google Scholar]